1887

Journal of General Virology header logo

Volume 74, Issue 10

Conformation-dependent recognition of baculovirus-expressed Epstein—Barr virus gp350 by a panel of monoclonal antibodies Free

Abstract

The Epstein—Barr virus (EBV) major membrane protein, gp350, induces antibodies that neutralize virus infectivity and is a potential candidate for an EBV vaccine. Full-length EBV gp350 and five protein fragments, encompassing the entire protein sequence, were generated in a baculovirus expression system. The recombinant proteins were analysed using a panel of 14 monoclonal antibodies (MAbs) (13 prepared against native gp350 derived from virus-producing cells and one prepared against an recombinant protein). All 14 MAbs, including a virus-neutralizing antibody, reacted with the full-length recombinant gp350 in a dot blot immunoassay, but only four of the 14 MAbs reacted with polypeptides expressed by the five sub-clones, indicating that the full-length protein, but not the protein fragments, was antigenically similar to native gp350. Treatment of the six recombinant proteins with peptide--glycosidase F (PNGase F) indicated that the full-length gp350 protein and the N-terminal fragment were glycosylated and that the four internally initiated polypeptides were not glycosylated. PNGase F treatment of the full-length glycosylated gp350 did not eliminate its reactivity with all of the 10 MAbs examined (including the neutralizing MAb) in a dot blot immunoassay; however, denatured glycosylated gp350 lost reactivity with all but four of the 14 MAbs when analysed by either dot blot or Western blot immunoassay. The data suggest that conformational epitopes are more important in recognition of gp350 by this panel of MAbs than glycosylation sites, and that the epitope on gp350 recognized by the neutralizing MAb is conformation-and not glycosylation-dependent.

  • Received:
  • Accepted:
  • Published Online:
© Journal of General Virology 1993
Loading

Article metrics loading...

/content/journal/jgv/10.1099/0022-1317-74-10-2171
1993-10-01
2024-04-24
Loading full text...

Full text loading...

/deliver/fulltext/jgv/74/10/JV0740102171.html?itemId=/content/journal/jgv/10.1099/0022-1317-74-10-2171&mimeType=html&fmt=ahah

References

  1. Arrand J. R., Rymo L., Walsh J. E., Bjorck E., Lindahl T., Griffin B. E. 1981; Molecular cloning of the complete Epstein–Barr virus genome as a set of overlapping restriction endonuclease fragments. Nucleic Acids Research 9:2999–3014
     [Google Scholar]
  2. Beisel C., Tanner J., Matsuo T., Thorley-Lawson D., Kezdy F., Kibff E. 1985; Two major outer envelope glycoproteins of Epstein–Barr virus are encoded by the same gene. Journal of Virology 54:665–674
     [Google Scholar]
  3. Bejarano M. T., Masucci M. G., Morgan A., Morein B., Klein G., Klein E. 1990; Epstein-Barr virus (EBV) antigens processed and presented by B cells, B blasts, and macrophages trigger T-cell-mediated inhibition of EBV-induced B-cell transformation. Journal of Virology 64:1398–1401
     [Google Scholar]
  4. Biggin M., Farrell P. J., Barrell B. G. 1984; Transcription and DNA sequence of the BamHI L fragment of B95-8 Epstein–Barr virus. EMBO Journal 3:1083–1090
     [Google Scholar]
  5. Conway M., Morgan A., Mackett M. 1989; Expression of Epstein–Barr virus membrane antigen gp340/220 in mouse fibroblasts using a bovine papillomavirus vector. Journal of General Virology 70:729–734
     [Google Scholar]
  6. Edson C. M., Thorley-Lawson D. A. 1981; Epstein–Barr virus membrane antigens: characterization, distribution and strain differences. Journal of Virology 39:172–184
     [Google Scholar]
  7. Edson C. M., Thorley-Lawson D. A. 1983; Synthesis and processing of the three major envelope glycoproteins of Epstein–Barr virus. Journal of Virology 46:547–556
     [Google Scholar]
  8. Emini E. A., Schleif W. A., Armstrong M. E., Silberklang M., Schultz L. D., Lehman D., Maigetter R., Qualtiere L. F., Pearson G. R., Ellis R. W. 1988; Antigenic analysis of the Epstein–Barr virus major membrane antigen (gp350/220) expressed in yeast and mammalian cells: implications for the development of a subunit vaccine. Virology 166:387–393
     [Google Scholar]
  9. Epstein M. A., Achong B. G. 1979; The relationship of the virus to Burkitt’s lymphoma. In The Epstein–Barr Virus pp 321–337 Edited by Epstein M. A., Achong B. G. Berlin, Heidelberg & New York: Springer-Verlag;
     [Google Scholar]
  10. Epstein M. A., Morgan A. J., Finerty S., Randle B. J., Kirkwood J. K. 1985; Protection of cottontop tamarins against Epstein–Barr virus-induced malignant lymphoma by a prototype subunit vaccine. Nature, London 318:287–289
     [Google Scholar]
  11. Epstein M. A., Randle B. J., Finerty S., Kirkwood J. K. 1986; Not all potently neutralizing, vaccine-induced antibodies to Epstein– Barr virus ensure protection of susceptible experimental animals. Clinical and Experimental Immunology 63:485–190
     [Google Scholar]
  12. Finerty S., Tarlton J., Mackett M., Conway M., Arrand J. R., Watkins P. E., Morgan A. J. 1992; Protective immunization against Epstein–Barr virus-induced disease in cottontop tamarins using the virus envelope glycoprotein gp340 produced from a bovine papillomavirus expression vector. Journal of General Virology 73:449–153
     [Google Scholar]
  13. Fingeroth J. D., Weis J. J., Tedder T. F., Strominger J. L., Biro P. A., Fearon D. T. 1984; Epstein–Barr virus receptor of human B lymphocytes is the C3d receptor CR2. Proceedings of the National Academy of Sciences, U,. S,. A 81:4510–4514
     [Google Scholar]
  14. Gong M., Kieff E. 1990; Intracellular trafficking of two major Epstein–Barr virus glycoproteins, gp350/220 and gp110. Journal of Virology 64:1507–1516
     [Google Scholar]
  15. Henle G., Henle W. 1979; The virus as the etiologic agent of infectious mononucleosis. In The Epstein–Barr Virus pp 297–320 Edited by Epstein M. A., Achong B. G. Berlin, Heidelberg & New York: Springer-Verlag;
     [Google Scholar]
  16. Hoffman G. J., Lazarowitz S. G., Hayward S. D. 1980; Monoclonal antibody against a 250, 000-dalton glycoprotein of Epstein–Barr virus identifies a membrane antigen and a neutralizing antigen. Proceedings of the National Academy of Sciences, U,. S,. A 77:2979–2983
     [Google Scholar]
  17. Hummel M., Thorley-Lawson D., Kieff E. 1984; An Epstein– Barr vims DNA fragment encodes messages for the two major envelope glycoproteins (gp350/300 and 220/200). Journal of Virology 49:413–417
     [Google Scholar]
  18. Kawasaki E. S. 1990; Sample preparation from blood, cell, and other fluid. In PCR Protocols: A Guide to Methods and Applications pp 146–152 Edited by Innis M. A. Gelfand D. H., Sninsky J. J., White T. J. San Diego: Academic Press;
     [Google Scholar]
  19. Klein G. 1979; The relationship of the virus to nasopharyngeal carcinoma. In The Epstein–Barr Virus pp 339–350 Edited by Epstein M. A., Achong B. G. Berlin, Heidelberg & New York: Springer-Verlag;
     [Google Scholar]
  20. Kornfeld R., Kornfeld S. 1985; Assembly of asparagine-linked oligosaccharides. Annual Review of Biochemistry 54:631–664
     [Google Scholar]
  21. Lowe R. S., Keller P. M., Keech B. J., Davison A. J., Whang Y., Morgan A. J., Kieff E., Ellis R. W. 1987; Varicella-zoster virus as a live vector for the expression of foreign genes. Proceedings of the National Academy of Sciences, U,. S,. A 84:3896–3900
     [Google Scholar]
  22. Luckow V. A., Summers M. D. 1988; Trends in the development of baculovirus expression vectors. Bio/Technology 6:47–55
     [Google Scholar]
  23. Mackett M., Arrand J. R. 1985; Recombinant vaccinia vims induces neutralising antibodies in rabbits against Epstein–Barr virus membrane antigen gp340. EMBO Journal 4:3229–3234
     [Google Scholar]
  24. Marcus-Sekura C. J., Woerner A. M., Zweig M., Court D. L., Levin J. G., Klutch M. 1990; Expression of HIV-1 integrase in E. coil, immunological analysis of the recombinant protein. AIDS Research and Human Retroviruses 6:1399–1408
     [Google Scholar]
  25. Morgan A. J., Epstein M. A., North J. R. 1984; Comparative immunogenicity studies on Epstein–Barr virus membrane antigen (MA) gp340 with novel adjuvants in mice, rabbits, and cotton-top tamarins. Journal of Medical Virology 13:281–292
     [Google Scholar]
  26. Mullis K. B., Faloona F. A. 1987; Specific synthesis of DNA in vitro via a polymerase-catalyzed chain reaction. Methods in Enzymology 155:335–350
     [Google Scholar]
  27. Nemerow G. R., Wolfert R., McNaughton M. E., Cooper N. R. 1985; Identification and characterization of the Epstein–Barr virus receptor on human B lymphocytes and its relationship to the C3d complement receptor (CR2). Journal of Virology 55:347–351
     [Google Scholar]
  28. Nemerow G. R., Houghten R. A., Moore M. D., Cooper N. R. 1989; Identification of an epitope in the major envelope protein of Epstein–Barr virus that mediates viral binding to the lymphocyte EBV receptor (CR2). Cell 56:369–377
     [Google Scholar]
  29. North J. R., Morgan A. J., Thompson J. L., Epstein M. A. 1982; Purified Epstein–Barr virus Mr 340, 000 glycoprotein induces potent vimsneutralizing antibodies when incorporated in liposomes. Proceedings of the National Academy of Sciences, U,. S,. A. 79:7504–7508
     [Google Scholar]
  30. Pither R. J., Nolan L., Tarlton J., Walford J., Morgan A. J. 1992a; Distribution of epitopes within the amino acid sequence of the Epstein–Barr virus major envelope glycoprotein, gp340, recognized by hyperimmune rabbit sera. Journal of General Virology 73:1409–1415
     [Google Scholar]
  31. Pither R. J., Zhang C. X., Shiels C., Tarlton J., Finerty S., Morgan A. J. 1992b; Mapping of B-cell epitopes on the polypeptide chain of the Epstein–Barr virus major envelope glycoprotein and candidate vaccine molecule gp340. Journal of Virology 66:1246–1251
     [Google Scholar]
  32. Qualtiere L. F., Chase R., Vorman B., Pearson G. R. 1982; Identification of Epstein–Barr virus strain differences with monoclonal antibodies to a membrane glycoprotein. Proceedings of the National Academy of Sciences, U,. S,. A 79:616–620
     [Google Scholar]
  33. Qualtiere L. F., Decoteau J. F., Hassan Nasr-El-Din M. 1987; Epitope mapping of the major Epstein–Barr vims outer envelope glycoprotein gp350/220. Journal of General Virology 68:535–543
     [Google Scholar]
  34. Ragot T., Finerty S., Watkins P. E., Perricaudet M., Morgan A. J. 1993; Replication-defective recombinant adenovirus expressing the Epstein–Barr virus (EBV) envelope glycoprotein gp340/220 induces protective immunity against EBV-induced lymphomas in the cottontop tamarin. Journal of General Virology 74:501–507
     [Google Scholar]
  35. Schultz L. D., Tanner J., Hofmann K. J., Emini E. A., Condra J. H., Jones R. E., Kieff E., Ellis R. W. 1987; Expression and secretion in yeast of a 400-kDa envelope glycoprotein derived from Epstein–Barr virus. Gene 54:113–123
     [Google Scholar]
  36. Serafini-Cessi F., Malagolini N., Nanni M., Dall’Olio F., Campadelli-Fiume G., Tanner J., Kieff E. 1989; Characterization of N- and O-linked oligosaccharides of glycoprotein 350 from Epstein–Barr virus. Virology 170:1–10
     [Google Scholar]
  37. Singer C., Knauert F., Bushar G., Klutch M., Lundquist R., Quinnan G. V. 1989; Quantitation of poliovirus antigens in inactivated viral vaccines by enzyme-linked immunosorbent assay using animal sera and monoclonal antibodies. Journal of Biological Standardization 17:137–150
     [Google Scholar]
  38. Strnad B. C., Adams M. R., Rabin H. 1983; Glycosylation pathways of two major Epstein–Barr virus membrane antigens. Virology 127:168–176
     [Google Scholar]
  39. Summers M. D., Smith G. E. 1987; A manual of methods for baculovirus vectors and insect cell culture procedures. Texas Agricultural Experiment Station Bulletin no 1555
     [Google Scholar]
  40. Tanner J., Whang Y., Sample J., Sears A., Kieff E. 1988; Soluble gp350/220 and deletion mutant glycoproteins block Epstein– Barr virus adsorption to lymphocytes. Journal of Virology 62:4452–1464
     [Google Scholar]
  41. Tarentino A. L., Gomez C. M., Plummer T. H. 1985; Deglycosylation of asparagine-linked glycans by peptide: N-glycosidase F. Biochemistry 24:4665–4671
     [Google Scholar]
  42. Thorley-Lawson D. A. 1979; A virus-free immunogen effective against Epstein–Barr virus. Nature, London 281:486–488
     [Google Scholar]
  43. Thorley-Lawson D. A., Geilinger K. 1980; Monoclonal antibodies against the major glycoprotein (gp350/220) of Epstein– Barr virus neutralize infectivity. Proceedings of the National Academy of Sciences, U,. S,. A. 77:5307–5311
     [Google Scholar]
  44. Thorley-Lawson D. A., Poodry C. A. 1982; Identification and isolation of the main component (gp350-gp220) of Epstein–Barr virus responsible for generating neutralizing antibodies in vivo. Journal of Virology 43:730–736
     [Google Scholar]
  45. Ulaeto D., Wallace L., Morgan A., Morein B., Rickinson A. B. 1988; In vitro T cell responses to a candidate Epstein–Barr virus vaccine: human CD4+ T cell clones specific for the major envelope glycoprotein gp340. European Journal of Immunology 18:1689–1697
     [Google Scholar]
  46. Vialard J., Lalumiere M., Vernet T., Briedis D., Alkhatib G., Henning D., Levin D., Richardson C. 1990; Synthesis of the membrane fusion and hemagglutinin proteins of measles virus, using a novel baculovirus vector containing the β-galactosidase gene. Journal of Virology 64:37–50
     [Google Scholar]
  47. Wallace L. E., Wright J., Ulaeto D. O., Morgan A. J., Rickinson A. B. 1991; Identification of two T-cell epitopes on the candidate Epstein–Barr virus vaccine glycoprotein gp340 recognized by CD4+ T-cell clones. Journal of Virology 65:3821–3828
     [Google Scholar]
  48. Wells A., Koide N., Klein G. 1982; Two large virion envelope glycoproteins mediate Epstein–Barr virus binding to receptorpositive cells. Journal of Virology 41:286–297
     [Google Scholar]
  49. Whang Y., Silberklang M., Morgan A., Munshi S., Lenny A. B., Ellis R. W., Kieff E. 1987; Expression of the Epstein–Barr virus gp350/220 gene in rodent and primate cells. Journal of Virology 61:1796–1807
     [Google Scholar]
  50. Zhang P. -F., Klutch M., Armstrong G., Qualtiere L., Pearson G., Marcus-Sekura C. J. 1991; Mapping of the epitopes of Epstein–Barr virus gp350 using monoclonal antibodies and recombinant proteins expressed in Escherichia coli defines three antigenic determinants. Journal of General Virology 72:2747–2755
     [Google Scholar]
http://instance.metastore.ingenta.com/content/journal/jgv/10.1099/0022-1317-74-10-2171
Loading
Conformation-dependent recognition of baculovirus-expressed Epstein—Barr virus gp350 by a panel of monoclonal antibodies
J. Gen. Virol. 74, 2171 (1993); https://doi.org/10.1099/0022-1317-74-10-2171
/content/journal/jgv/10.1099/0022-1317-74-10-2171
/content/journal/jgv/10.1099/0022-1317-74-10-2171
Loading

Data & Media loading...

Most cited Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error